If only
Cambridge-based Bango (Aim: BGO) develops technology that enables payments to be made via mobile phones. Bango collects a fee on each transaction made. Revenue was up by 200% in the year to 31 December, with strong growth predicted this year too. Losses narrowed to £4.6m from £5m the year before, and the firm expects to break even in the "near term", with profitability coming in the "medium term". The shares have risen by more than 150% in the last 12 months.
Be glad you didn't
Pharmaceutical firm Vernalis (Aim: VER) markets cough and cold medicine, antibiotics and migraine treatments in the US via its office in Pennsylvania, with more cough and cold products under development at its research centre in the UK. Latest interim results for the six months to
31 December showed losses rising and revenue falling. But the firm has plenty of cash and no debt. Investors have been abandoning the shares, however. The stock price is down by more than 50% in the last year.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
Barclays begins paying up to £100 compensation to customers after banking outageBarclays will pay up to £7.5 million in compensation to customers after its banking services were disrupted by an IT outage
-
Review: Shangri-La Paris – an ode to the world’s best foodNatasha Langan enjoys fine French and Chinese cuisine at the Shangri-La Paris
